Pharmaceutical, Medical Device Industries Concerned About Sharfstein As FDA Deputy Director
Main Category: Regulatory Affairs / Drug ApprovalsAlso Included In: Pharma Industry / Biotech Industry; Medical Devices / Diagnostics
Article Date: 20 Mar 2009 - 6:00 PDT
| Patient / Public: | ![]() | |
| Healthcare Prof: | ![]() |
The pharmaceutical and medical device industries have praised the nomination of former New York City Health Commissioner Margaret Hamburg as FDA commissioner, but they are "nervous in varying degrees" about the nomination of Baltimore Health Commissioner Joshua Sharfstein as principal deputy commissioner of the agency, CongressDaily reports.
According to one lobbyist, Sharfstein likely "will have a certain amount of autonomy on pharmaceuticals and medical devices," as Hamburg likely will focus on food safety and tobacco regulation. The lobbyist added, "Companies are clearly going to get more scrutiny" under Sharfstein.
As a former staffer for House Energy and Commerce Committee Chair Henry Waxman (D-Calif.), who "has been tough on drug companies," Sharfstein "has a long and sometimes contentious history with the pharmaceutical industry," CongressDaily reports. "Sharfstein has carried the torch on many of his boss's public health priorities" -- such as efforts to limit off-label use of medications and gifts from pharmaceutical companies to physicians -- and he "could play a key role implementing 2007 FDA legislation" that requires pharmaceutical companies to develop risk evaluation and mitigation strategies, according to CongressDaily.
Peter Pitts, a former FDA associate commissioner for external affairs and co-founder of the Center for Medicine in the Public Interest, said that many of the concerns about Sharfstein raised by the pharmaceutical and medical device industries are unfounded. "I don't think you'll see more strident regulations," he said, adding, "I think you'll see a more effective way to use existing regulation" (Edney, CongressDaily, 3/18).
Reprinted with kind permission from http://www.kaisernetwork.org. You can view the entire Kaiser Daily Health Policy Report, search the archives, or sign up for email delivery at http://www.kaisernetwork.org/dailyreports/healthpolicy. The Kaiser Daily Health Policy Report is published for kaisernetwork.org, a free service of The Henry J. Kaiser Family Foundation.
© 2009 Advisory Board Company and Kaiser Family Foundation. All rights reserved.
Visit our regulatory affairs / drug approvals section for the latest news on this subject.
MLA
13 Feb. 2012. <http://www.medicalnewstoday.com/releases/143035.php>
APA
http://www.medicalnewstoday.com/releases/143035.php.
Please note: If no author information is provided, the source is cited instead.
|
Rate this article: (Hover over the stars then click to rate) |
Patient / Public: |
or |
Health Professional: |
Add Your Opinion
Please note that we publish your name, but we do not publish your email address. It is only used to let you know when your message is published. We do not use it for any other purpose. Please see our privacy policy for more information.
If you write about specific medications or operations, please do not name health care professionals by name.
All opinions are moderated before being included (to stop spam)
Contact Our News Editors
For any corrections of factual information, or to contact the editors please use our feedback form.
![]()
Please send any medical news or health news press releases to:
Note: Any medical information published on this website is not intended as a substitute for informed medical advice and you should not take any action before consulting with a health care professional. For more information, please read our terms and conditions.



